该结果基于中国妇女18-25岁群体AS04‐HPV‐16/18疫苗效力、安全性和免疫原性的随机对照双盲实验。HPV2价疫苗对HPV‐31 (59.6% [95% CI: 39.4, 73.5])、HPV‐33 (42.7% [95% CI: 15.6, 61.6])和HPV‐45 (54.8% [95% CI: 19.3, 75.6])的机会感染具有保护效力，对6个月和12个月持续HPV‐31感染具有保护效力 (分别为64.6% [95% CI: 27.6, 83.9]和81.3% [95% CI: 34.5, 96.5])。此外对HPV‐31 (62.5% [95% CI: 25.2, 82.4])和HPV‐33 (46.7% [95% CI: 1.1, 72.2])相关的ASCUS+具有保护效力。对HPV‐31/33/45相关的CIN1+的疫苗效力为36.1% (95% CI: −80.5, 79.0)，对HPV‐31/33/45相关的CIN2+的疫苗效力为74.9% (95% CI: −25.8, 97.4)。

参考文献：Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF, Yang X, Yu JX, Zhu J, Zhu Y, Chen F, Zhang Q, Wang H, Wang C, Bi J, Xue S, Shen L, Zhang YS, He Y, Tang H, Karkada N, Suryakiran P, Bi D, Struyf F. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019 Oct;8(14):6195-6211. doi: 10.1002/cam4.2399. Epub 2019 Jul 15. PMID: 31305011; PMCID: PMC6797633.